These results were further supported by subsequent findings of the randomized, placebo-controlled, double-blind KEYNOTE-189 trial, which indicated significant benefits of adding first-line pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug for patients with metastatic nonsquamous NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.